CUSIP: 88338N107
What is CUSIP 88338N107?
CUSIP 88338N107 identifies TXMD - THERAPEUTICSMD INC - COM in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Open recent reporting periods for CUSIP 88338N107:
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2022 Q3 | 0 | $0 | -$138,000 | 0 | |
| 2022 Q2 | 13,882 | $138,000 | -$40,657,805 | $10.06 | 2 |
| 2022 Q1 | 106,249,720 | $40,383,995 | -$6,460,833 | $0.38 | 107 |
| 2021 Q4 | 123,989,841 | $44,113,283 | -$5,136,500 | $0.36 | 118 |
| 2021 Q3 | 132,623,961 | $98,181,827 | -$35,237,991 | $0.74 | 143 |
| 2021 Q2 | 168,594,448 | $200,534,644 | -$7,293,146 | $1.19 | 148 |
| 2021 Q1 | 174,027,984 | $233,195,315 | +$19,299,909 | $1.34 | 154 |
| 2020 Q4 | 161,086,122 | $195,000,979 | +$2,870,955 | $1.21 | 150 |
| 2020 Q3 | 157,569,577 | $249,322,171 | +$8,915,683 | $1.58 | 139 |
| 2020 Q2 | 152,335,132 | $190,408,846 | -$36,023,732 | $1.25 | 142 |
| 2020 Q1 | 182,844,612 | $189,844,871 | -$31,618,067 | $1.06 | 135 |
| 2019 Q4 | 192,502,060 | $466,882,212 | +$46,177,594 | $2.42 | 162 |
| 2019 Q3 | 172,591,588 | $626,565,901 | -$57,124,136 | $3.63 | 145 |
| 2019 Q2 | 188,901,090 | $489,428,303 | -$20,791,317 | $2.60 | 144 |
| 2019 Q1 | 191,057,703 | $930,418,803 | +$25,180,934 | $4.87 | 139 |
| 2018 Q4 | 186,489,933 | $710,578,290 | +$23,585,017 | $3.81 | 133 |
| 2018 Q3 | 178,040,270 | $1,167,923,446 | +$136,966,572 | $6.56 | 151 |
| 2018 Q2 | 157,165,492 | $980,713,228 | -$29,803,080 | $6.24 | 141 |
| 2018 Q1 | 162,504,460 | $791,412,125 | -$4,590,259 | $4.87 | 139 |
| 2017 Q4 | 162,564,564 | $981,884,925 | -$9,661,276 | $6.04 | 140 |
| 2017 Q3 | 164,535,449 | $866,656,619 | +$45,414,189 | $5.29 | 132 |
| 2017 Q2 | 155,831,246 | $821,246,855 | -$59,727,020 | $5.27 | 116 |
| 2017 Q1 | 164,032,510 | $1,180,505,857 | +$86,656,418 | $7.20 | 133 |
| 2016 Q4 | 164,362,294 | $948,393,873 | +$51,055,130 | $5.77 | 144 |
| 2016 Q3 | 155,172,033 | $1,056,251,015 | -$38,331,278 | $6.81 | 134 |
| 2016 Q2 | 160,166,119 | $1,361,401,786 | +$63,580,566 | $8.50 | 122 |
| 2016 Q1 | 152,957,072 | $978,874,720 | +$151,271,708 | $6.40 | 127 |
| 2015 Q4 | 128,656,848 | $1,334,216,025 | +$78,466,830 | $10.37 | 124 |
| 2015 Q3 | 122,266,742 | $716,480,520 | +$70,338,173 | $5.86 | 113 |
| 2015 Q2 | 109,322,381 | $859,225,513 | -$17,806,752 | $7.86 | 113 |
| 2015 Q1 | 112,516,421 | $680,746,484 | +$103,006,656 | $6.05 | 93 |
| 2014 Q4 | 95,559,938 | $425,226,112 | +$1,098,617 | $4.45 | 79 |
| 2014 Q3 | 95,310,793 | $442,156,817 | +$40,553,725 | $4.64 | 80 |
| 2014 Q2 | 86,674,105 | $383,021,167 | -$34,265,495 | $4.42 | 85 |
| 2014 Q1 | 91,996,558 | $580,382,712 | +$141,497,858 | $6.31 | 81 |